146 related articles for article (PubMed ID: 35166242)
101. CUB Domain-Containing Protein 1 (CDCP1) is a rational target for the development of imaging tracers and antibody-drug conjugates for cancer detection and therapy.
Khan T; Lyons NJ; Gough M; Kwah KKX; Cuda TJ; Snell CE; Tse BW; Sokolowski KA; Pearce LA; Adams TE; Rose SE; Puttick S; Pajic M; Adams MN; He Y; Hooper JD; Kryza T
Theranostics; 2022; 12(16):6915-6930. PubMed ID: 36276654
[No Abstract] [Full Text] [Related]
102. Theranostic Targeting of CUB Domain-Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer.
Chopra S; Trepka K; Sakhamuri S; Carretero-González A; Zhu J; Egusa E; Zhou J; Leung K; Zhao N; Hooshdaran N; Feng FY; Wells JA; Chou J; Evans MJ
Clin Cancer Res; 2023 Apr; 29(7):1232-1242. PubMed ID: 36648492
[TBL] [Abstract][Full Text] [Related]
103. AXL/CDCP1/SRC axis confers acquired resistance to osimertinib in lung cancer.
Murakami Y; Kusakabe D; Watari K; Kawahara A; Azuma K; Akiba J; Taniguchi M; Kuwano M; Ono M
Sci Rep; 2022 May; 12(1):8983. PubMed ID: 35643725
[TBL] [Abstract][Full Text] [Related]
104. The CDCP1 Signaling Hub: A Target for Cancer Detection and Therapeutic Intervention.
Khan T; Kryza T; Lyons NJ; He Y; Hooper JD
Cancer Res; 2021 May; 81(9):2259-2269. PubMed ID: 33509939
[TBL] [Abstract][Full Text] [Related]
105. CDCP1: A promising diagnostic biomarker and therapeutic target for human cancer.
Qi X; Gao J; Li Z; Zhang G; Li J; Fu Y; Cai M; Wang H; Tong T
Life Sci; 2022 Jul; 301():120600. PubMed ID: 35504333
[TBL] [Abstract][Full Text] [Related]
106. Cleaved CDCP1 marks the spot: a neoepitope for RAS-driven cancers.
Donahue KL; Pasca di Magliano M
J Clin Invest; 2022 Feb; 132(4):. PubMed ID: 35166242
[TBL] [Abstract][Full Text] [Related]
107. Effective targeting of intact and proteolysed CDCP1 for imaging and treatment of pancreatic ductal adenocarcinoma.
Kryza T; Khan T; Puttick S; Li C; Sokolowski KA; Tse BW; Cuda T; Lyons N; Gough M; Yin J; Parkin A; Deryugina EI; Quigley JP; Law RHP; Whisstock JC; Riddell AD; Barbour AP; Wyld DK; Thomas PA; Rose S; Snell CE; Pajic M; He Y; Hooper JD
Theranostics; 2020; 10(9):4116-4133. PubMed ID: 32226543
[No Abstract] [Full Text] [Related]
108. CUB Domain-containing Protein 1 (CDCP1) Is Down-regulated by Active Hexose-correlated Compound in Human Pancreatic Cancer Cells.
Kuhara K; Tokuda K; Kitagawa T; Baron B; Tokunaga M; Harada K; Terasaki M; Uehara O; Ohta T; Takai R; Hamada JI; Kobayashi M; Shimo T; Nagayasu H; Kuramitsu Y
Anticancer Res; 2018 Nov; 38(11):6107-6111. PubMed ID: 30396925
[TBL] [Abstract][Full Text] [Related]
109. CUB domain-containing protein 1, a prognostic factor for human pancreatic cancers, promotes cell migration and extracellular matrix degradation.
Miyazawa Y; Uekita T; Hiraoka N; Fujii S; Kosuge T; Kanai Y; Nojima Y; Sakai R
Cancer Res; 2010 Jun; 70(12):5136-46. PubMed ID: 20501830
[TBL] [Abstract][Full Text] [Related]
110. In vivo cleaved CDCP1 promotes early tumor dissemination via complexing with activated β1 integrin and induction of FAK/PI3K/Akt motility signaling.
Casar B; Rimann I; Kato H; Shattil SJ; Quigley JP; Deryugina EI
Oncogene; 2014 Jan; 33(2):255-68. PubMed ID: 23208492
[TBL] [Abstract][Full Text] [Related]
111. Targeting a proteolytic neoepitope on CUB domain containing protein 1 (CDCP1) for RAS-driven cancers.
Lim SA; Zhou J; Martinko AJ; Wang YH; Filippova EV; Steri V; Wang D; Remesh SG; Liu J; Hann B; Kossiakoff AA; Evans MJ; Leung KK; Wells JA
J Clin Invest; 2022 Feb; 132(4):. PubMed ID: 35166238
[TBL] [Abstract][Full Text] [Related]
112. The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer.
Freed-Pastor WA; Lambert LJ; Ely ZA; Pattada NB; Bhutkar A; Eng G; Mercer KL; Garcia AP; Lin L; Rideout WM; Hwang WL; Schenkel JM; Jaeger AM; Bronson RT; Westcott PMK; Hether TD; Divakar P; Reeves JW; Deshpande V; Delorey T; Phillips D; Yilmaz OH; Regev A; Jacks T
Cancer Cell; 2021 Oct; 39(10):1342-1360.e14. PubMed ID: 34358448
[TBL] [Abstract][Full Text] [Related]
113. Multimodal Mapping of the Tumor and Peripheral Blood Immune Landscape in Human Pancreatic Cancer.
Steele NG; Carpenter ES; Kemp SB; Sirihorachai VR; The S; Delrosario L; Lazarus J; Amir ED; Gunchick V; Espinoza C; Bell S; Harris L; Lima F; Irizarry-Negron V; Paglia D; Macchia J; Chu AKY; Schofield H; Wamsteker EJ; Kwon R; Schulman A; Prabhu A; Law R; Sondhi A; Yu J; Patel A; Donahue K; Nathan H; Cho C; Anderson MA; Sahai V; Lyssiotis CA; Zou W; Allen BL; Rao A; Crawford HC; Bednar F; Frankel TL; Pasca di Magliano M
Nat Cancer; 2020 Nov; 1(11):1097-1112. PubMed ID: 34296197
[TBL] [Abstract][Full Text] [Related]
114. The biological underpinnings of therapeutic resistance in pancreatic cancer.
Beatty GL; Werba G; Lyssiotis CA; Simeone DM
Genes Dev; 2021 Jul; 35(13-14):940-962. PubMed ID: 34117095
[TBL] [Abstract][Full Text] [Related]
115.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
116.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
117.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
118.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
119.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
120.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
